Viriom Announces Interim Results from Phase 3 Clinical Trials with Elsulfavirine Were Presented at Largest Events on HIV/AIDS in Moscow

Viriom Announces Interim Results from Phase 3 Clinical Trials with Elsulfavirine Were Presented at Largest Events on HIV/AIDS in Moscow

April 7, 2016 – Viriom, a member of the ChemRar High-Tech Center, announced today that interim results from Phase 3 clinical trials with the drug Elsulfavirine, a new highly selective non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV/AIDS, have been presented to the Russian and international communities at notable events on HIV infection held in Moscow recently.

From March 23 to 25, 2016, Moscow hosted the Fifth International Conference on HIV/AIDS in Eastern Europe and Central Asia. It is the largest forum for prevention and treatment of HIV in the region, organized by the Russian Federation and the Joint United Nations Programme on HIV/AIDS (UNAIDS). It is a prestigious conference, held regularly, which gathers the world's leading scientists, politicians, and representatives of international organizations and communities of people living with HIV.

From March 28 to 30, 2016, the VII Annual Russian Congress on Infectious Diseases was held, attracting over 2,000 participants including scientists in the fields of infectious diseases and epidemiology, doctors, and representatives from federal and regional health authorities from 84 Russian regions and six foreign countries (Belarus, Italy, France, Guinea, Tajikistan, Uzbekistan). For more information about the event, visit http://www.congress-infection.ru/.

Alexey V. Kravchenko, Professor, MD, a leading researcher at the Department of AIDS Prevention and Control of the Central Research Institute of Epidemiology, presented the report, "The efficacy and safety of new domestic NNRTI (VM-1500 Elpivirin) compared with EFV drug as part of ART regimens in HIV-1-infected patients who had not previously received treatment" at both events. He stated that according to preliminary data from the clinical trials, both treatment regimens show equal virologic and immunologic efficacy, and convincing evidence exists indicating greater safety for the ART regimen containing 20 mg Elsulfavirine in comparison to the regimen that contains EFV.

The "Viriom" project on the development of innovative medicines for the treatment of HIV-infected patients was supported by the Russian Ministry of Industry and Trade within the framework of the Federal Program "Development of the Russian Federation, the pharmaceutical and medical industry for the period until 2020 and beyond."

About Viriom

Viriom, Inc. is a late-stage biotech company developing, manufacturing and distributing novel and affordable therapies against life threatening HIV infection. The company has an exclusive worldwide license to its Phase 2-3 HIV oral treatment Elsulfavirine from F. Hoffmann-La Roche. Viriom believes its drug candidates are capable of making a breakthrough in treating and preventing HIV infection in both developing and developed countries. For more information, please visit www.viriom.com.